Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
04 Jun 2019 05:38 PM
RNS
Holdings in Company
04 Jun 2019 09:59 AM
RNS
Total Voting Rights
03 Jun 2019 06:06 PM
RNS
Holding(s) in Company
03 Jun 2019 10:31 AM
RNS
Total Voting Rights
29 May 2019 06:19 PM
RNS
Exercise of Subscription Option by Novo Holdings
29 May 2019 01:06 PM
RNS
Result of AGM
28 May 2019 07:00 AM
RNS
Strategic Investment by Novo Holdings A/S
23 May 2019 06:04 PM
RNS
Director Dealings / Market Share Purchase
02 May 2019 02:53 PM
RNS
Long Term Incentive Plan Option Grant
01 May 2019 12:52 PM
RNS
REPLACEMENT: Total Voting Rights
01 May 2019 11:33 AM
RNS
Total Voting Rights
30 Apr 2019 05:38 PM
RNS
Holdings in Company
30 Apr 2019 01:35 PM
RNS
Oxford Biomedica to present at the ASGCT
30 Apr 2019 01:15 PM
RNS
Axovant doses second cohort of AXO-Lenti-PD
25 Apr 2019 03:38 PM
RNS
Director Dealings / Market Share Purchase
23 Apr 2019 01:47 PM
RNS
Deferred Bonus Plan and LTIP Option Grants
23 Apr 2019 11:38 AM
RNS
Director Dealings / Market Share Transactions
18 Apr 2019 05:33 PM
RNS
Exercise of warrants
18 Apr 2019 07:00 AM
RNS
Annual Report and Accounts & AGM Notification
02 Apr 2019 07:15 AM
EQS
Oxford BioMedica (OXB): Deal-making drives firs...
01 Apr 2019 11:40 AM
RNS
Total Voting Rights
26 Mar 2019 12:57 PM
RNS
Director Dealings / Market Share Purchase
26 Mar 2019 08:25 AM
RNS
Japanese approval of Kymriah® (tisagenlecleucel)
14 Mar 2019 07:00 AM
RNS
Preliminary Results
12 Mar 2019 07:00 AM
RNS
OXB announces R&D collaboration with Microsoft
11 Mar 2019 10:38 AM
RNS
Axovant's update on Phase 2 trial of AXO-Lenti-PD
01 Mar 2019 09:30 AM
RNS
Total Voting Rights
25 Feb 2019 12:23 PM
RNS
Director Dealings / Market Share Purchase
08 Feb 2019 07:00 AM
RNS
Notice of Results
07 Feb 2019 11:49 AM
RNS
Director/PDMR Shareholding
07 Feb 2019 09:22 AM
RNS
Update on programmes outlicensed to Sanofi
06 Feb 2019 11:00 AM
RNS
Director Dealings / Market Share Transactions
05 Feb 2019 10:22 AM
RNS
Director Dealings / Market Share Purchase
01 Feb 2019 10:00 AM
RNS
Total Voting Rights
24 Jan 2019 11:20 AM
RNS
Director Dealings / Market Share Purchase
18 Jan 2019 10:51 AM
RNS
Director Dealings / Market Share Purchase
03 Jan 2019 12:20 PM
RNS
Block listing Interim Review
02 Jan 2019 10:17 AM
RNS
Total Voting Rights
21 Dec 2018 01:16 PM
RNS
Director Dealings / Market Share Purchase
06 Dec 2018 04:11 PM
RNS
Axovant FDA meeting feedback
03 Dec 2018 09:53 AM
RNS
Total Voting Rights
03 Dec 2018 07:00 AM
RNS
Longer term Kymriah efficacy and safety data
23 Nov 2018 10:41 AM
RNS
Director Dealings
23 Nov 2018 07:00 AM
RNS
Oxford Biomedica form digital framework initiative
09 Nov 2018 07:00 AM
RNS
Block listing application
01 Nov 2018 02:41 PM
RNS
Total Voting Rights
25 Oct 2018 07:00 AM
RNS
Axovant Doses First Patient with AXO-Lenti-PD
22 Oct 2018 04:39 PM
RNS
Director Dealings / Market Share Purchase
05 Oct 2018 07:00 AM
RNS
Details of alliance with Orchard Therapeutics
01 Oct 2018 09:41 AM
RNS
Total Voting Rights

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100